Aldeyra Therapeutics (ALDX) Liabilities and Shareholders Equity (2013 - 2026)

Aldeyra Therapeutics (ALDX) has 14 years of Liabilities and Shareholders Equity data on file, last reported at $66.5 million in Q1 2026.

• Quarterly Liabilities and Shareholders Equity fell 28.66% year-over-year to $66.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $301.3 million (down 31.7% YoY) and the FY2025 annual result came in at $72.1 million, down 31.11% from the prior year.
• Liabilities and Shareholders Equity eased to $66.5 million in Q1 2026, from $72.1 million in the prior quarter.
• In the past five years, Liabilities and Shareholders Equity ranged from a high of $222.7 million in Q1 2022 to a low of $66.5 million in Q1 2026.
• A 5-year average of $135.2 million and a median of $141.3 million in 2024 frame the typical range for Liabilities and Shareholders Equity.
• Annual changes were most pronounced in 2022 — Liabilities and Shareholders Equity soared 51.18% — and 2025, when it slumped 34.04%.
• Tracing ALDX's Liabilities and Shareholders Equity over 5 years: stood at $181.3 million in 2022, then fell by 18.18% to $148.3 million in 2023, then decreased by 29.48% to $104.6 million in 2024, then tumbled by 31.11% to $72.1 million in 2025, then declined by 7.74% to $66.5 million in 2026.
• The last three Liabilities and Shareholders Equity figures came in at $66.5 million (Q1 2026), $72.1 million (Q4 2025), and $77.8 million (Q3 2025), per Business Quant data.